Edition:
United Kingdom

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

14.10USD
3:35pm BST
Change (% chg)

$-0.10 (-0.70%)
Prev Close
$14.20
Open
$14.10
Day's High
$14.20
Day's Low
$13.80
Volume
39,241
Avg. Vol
296,979
52-wk High
$22.45
52-wk Low
$8.68

Select another date:

Wed, Apr 18 2018

BRIEF-Alder Biopharmaceuticals Inc To Present New Phase 3 Migraine Prevention Data For Eptinezumab

* ALDER BIOPHARMACEUTICALS INC - TO PRESENT NEW PHASE 3 MIGRAINE PREVENTION DATA FOR EPTINEZUMAB AT 70TH ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING Source text for Eikon: Further company coverage:

BRIEF-Alder Biopharmaceuticals Appoints Erin Lavelle To Newly Created Role Of Chief Operating Officer

* ALDER BIOPHARMACEUTICALS® APPOINTS ERIN LAVELLE TO NEWLY CREATED ROLE OF CHIEF OPERATING OFFICER Source text for Eikon: Further company coverage:

BRIEF-Redmile Group Reports 9.99 Pct Stake In Alder Biopharmaceuticals

* REDMILE GROUP, LLC REPORTS 9.99 PERCENT STAKE IN ALDER BIOPHARMACEUTICALS INC AS OF MARCH 23, 2018 - SEC FILING‍​ Source text: (https://bit.ly/2HZWQqw)

BRIEF-Alder Biopharma Q4 Loss Per Share $0.80

* ALDER BIOPHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS

BRIEF-Alder Biopharmaceuticals Enters Into European Patent Settlement, Global License Agreement With Teva

* ALDER BIOPHARMACEUTICALS® ENTERS INTO EUROPEAN PATENT SETTLEMENT AND GLOBAL LICENSE AGREEMENT WITH TEVA IN THE FIELD OF ANTI-CGRP-BASED THERAPY

BRIEF-Alder Announces $250 Million Committed Equity Financing

* ALDER BIOPHARMACEUTICALS INC - INVESTORS TO PURCHASE UP TO $250 MILLION OF NON-VOTING CLASS A PREFERRED STOCK DURING 3-YEAR TERM OF AGREEMENT

BRIEF-Alder Says Eptinezumab Met Primary Endpoint In Pivotal Phase 3 Promise 2 Clinical Trial

* ALDER ANNOUNCES EPTINEZUMAB SIGNIFICANTLY REDUCES MIGRAINE RISK MEETS PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN PIVOTAL PROMISE 2 PHASE 3 TRIAL FOR CHRONIC MIGRAINE PREVENTION

BRIEF-Alder Biopharmaceuticals Q3 loss per share $0.92

* Alder biopharmaceuticals announces third quarter 2017 financial and operating results

Select another date: